Two distinct trajectories of clinical and neurodegeneration events in Parkinson's disease

被引:25
|
作者
Zhou, Cheng [1 ]
Wang, Linbo [2 ,3 ,4 ,5 ]
Cheng, Wei [2 ,3 ,4 ,5 ,6 ]
Lv, JinChao [2 ]
Guan, Xiaoujun [1 ]
Guo, Tao [1 ]
Wu, Jingjing [1 ]
Zhang, Wei [2 ,3 ,4 ,5 ]
Gao, Ting [7 ]
Liu, Xiaocao [1 ]
Bai, Xueqin [1 ]
Wu, Haoting [1 ]
Cao, Zhengye [1 ]
Gu, Luyan [7 ]
Chen, Jingwen [1 ]
Wen, Jiaqi [1 ]
Huang, Peiyu [1 ]
Xu, Xiaojun [1 ]
Zhang, Baorong [7 ]
Feng, Jianfeng [2 ,3 ,4 ,5 ,6 ]
Zhang, Minming [1 ]
机构
[1] Zhejiang Univ, Affiliated Hosp 2, Sch Med, Dept Radiol, Hangzhou 310000, Peoples R China
[2] Fudan Univ, Inst Sci & Technol Brain Inspired Intelligence, Shanghai 200433, Peoples R China
[3] Fudan Univ, Key Lab Computat Neurosci & Brain Inspired Intelli, Minist Educ, Shanghai, Peoples R China
[4] Fudan Univ, MOE Frontiers Ctr Brain Sci, Shanghai, Peoples R China
[5] Zhangjiang Fudan Int Innovat Ctr, Shanghai, Peoples R China
[6] Univ Warwick, Dept Comp Sci, Coventry CV4 7AL, England
[7] Zhejiang Univ, Affiliated Hosp 2, Sch Med, Dept Neurol, Hangzhou 310000, Peoples R China
基金
中国国家自然科学基金;
关键词
PROGRESSION MARKER; BIOMARKERS; PATHOLOGY; PATTERNS; SUBTYPES; ATROPHY;
D O I
10.1038/s41531-023-00556-3
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Increasing evidence suggests that Parkinson's disease (PD) exhibits disparate spatial and temporal patterns of progression. Here we used a machine-learning technique-Subtype and Stage Inference (SuStaIn) - to uncover PD subtypes with distinct trajectories of clinical and neurodegeneration events. We enrolled 228 PD patients and 119 healthy controls with comprehensive assessments of olfactory, autonomic, cognitive, sleep, and emotional function. The integrity of substantia nigra (SN), locus coeruleus (LC), amygdala, hippocampus, entorhinal cortex, and basal forebrain were assessed using diffusion and neuromelanin-sensitive MRI. SuStaIn model with above clinical and neuroimaging variables as input was conducted to identify PD subtypes. An independent dataset consisting of 153 PD patients and 67 healthy controls was utilized to validate our findings. We identified two distinct PD subtypes: subtype 1 with rapid eye movement sleep behavior disorder (RBD), autonomic dysfunction, and degeneration of the SN and LC as early manifestations, and cognitive impairment and limbic degeneration as advanced manifestations, while subtype 2 with hyposmia, cognitive impairment, and limbic degeneration as early manifestations, followed later by RBD and degeneration of the LC in advanced disease. Similar subtypes were shown in the validation dataset. Moreover, we found that subtype 1 had weaker levodopa response, more GBA mutations, and poorer prognosis than subtype 2. These findings provide new insights into the underlying disease biology and might be useful for personalized treatment for patients based on their subtype.
引用
收藏
页数:11
相关论文
共 50 条
  • [31] Neurodegeneration and cognition in Parkinson's disease: a review
    Ding, W.
    Ding, L. -J.
    Li, F. -F.
    Han, Y.
    Mu, L.
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2015, 19 (12) : 2275 - 2281
  • [32] Hypothetical mechanisms of neurodegeneration in Parkinson's disease
    Ruberg, M
    FranceLanord, V
    Lambeng, N
    Nguyen, TT
    Cerqueira, E
    Brugg, B
    Michel, PP
    Hunot, S
    Faucheux, B
    Hirsch, E
    Agid, Y
    JOURNAL OF NEUROCHEMISTRY, 1997, 69 : S140 - S140
  • [33] The Role of Ceruloplasmin in Neurodegeneration in Parkinson's Disease
    Gurer, Reyhan
    Aydin, Senay
    Gokce, Dilvin
    Ayaz, Tunahan
    Isik, Nihal
    TURKISH JOURNAL OF NEUROLOGY, 2016, 22 (01) : 19 - 25
  • [34] Neurodegeneration and Neuroregeneration in Experimental Parkinson's Disease
    Blandini, F.
    Cova, L.
    Armentero, M. -T.
    Bossolasco, P.
    Polli, E.
    Nappi, G.
    Silani, V.
    CELL TRANSPLANTATION, 2010, 19 (03) : 332 - 333
  • [35] CSF markers of neurodegeneration in Parkinson's disease
    Vranova, Hana Prikrylova
    Mares, Jan
    Nevrly, Martin
    Stejskal, David
    Zapletalova, Jana
    Hlustik, Petr
    Kanovsky, Petr
    JOURNAL OF NEURAL TRANSMISSION, 2010, 117 (10) : 1177 - 1181
  • [36] Linking Neuroinflammation and Neurodegeneration in Parkinson's Disease
    Gelders, Geraldine
    Baekelandt, Veerle
    Van der Perren, Anke
    JOURNAL OF IMMUNOLOGY RESEARCH, 2018, 2018
  • [37] Calpain Mediated Neurodegeneration in Parkinson’s disease
    V. H. Knaryan
    Neurochemical Journal, 2023, 17 : 632 - 638
  • [38] CSF markers of neurodegeneration in Parkinson’s disease
    Hana Přikrylová Vranová
    Jan Mareš
    Martin Nevrlý
    David Stejskal
    Jana Zapletalová
    Petr Hluštík
    Petr Kaňovský
    Journal of Neural Transmission, 2010, 117 : 1177 - 1181
  • [39] PET assessment of neurodegeneration in Parkinson's disease
    de la Fuente-Fernandez, R.
    PARKINSONISM & RELATED DISORDERS, 2009, 15 : S27 - S27
  • [40] The Effect of Levosimendan on Two Distinct Rodent Models of Parkinson's Disease
    Abuirmaileh, Amjad N.
    Alzoubi, Karem H.
    Rababa'h, Abeer M.
    CURRENT ALZHEIMER RESEARCH, 2020, 17 (11) : 1043 - 1051